Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

Abstract

A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and / or increasing bone density and / or improving healing of fractured bone and / or improving bone quality are administered for use in the treatment and / or prophylaxis of cartilage and / or bone conditions.

Description

FIELD OF THE INVENTION [0001] The present application relates to a combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and / or increasing bone density and / or improving healing of fractured bone and / or improving bone quality are administered for use in the treatment and / or prophylaxis of cartilage and / or bone conditions. BACKGROUND OF THE INVENTION [0002] Osteoporosis is the most common form of metabolic bone disease in humans. It is a condition, which affects a very large number of people all over the world, and as the number of elderly people is set to rise dramatically in the coming decades in most countries, the prevalence and impact of osteoporosis will also increase. The disease is characterized pathologically by an absolute decrease in the amount of bone mass and the structural quality of bone, and clinically by increased susceptibility to fractures. In fact, osteoporosis i...

AI Technical Summary

Benefits of technology

[0007] In one aspect, the invention relates to a method for the treatment and / or prophylaxis of a cartilage and / or bone disease and / or conditions resulting in a dysregulation of cartilage and / or bone metabolism in a mammal, such as, e.g., a human female or male adult, adolescent or a child, such as, e.g., osteoporosis, osteoarthritis, osteopetrosis, osteopenia and Paget's disease, hypercalcemia of malignancy, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, osteodystrophy, myositis ossificans, Bechterew's disease, malignant hypercalcemia, osteolytic lesions produced by bone metastasis, bone pain due to bone metastasis, bone loss due to sex steroid hormone deficiency, bone abnormalities due to steroid hormone treatment, bone abnormalities caused by cancer therapeutics, osteomalacia, Bechet's disease, hyperostosis, metastatic bone disease, immobilization-induced osteopenia or osteoporosis, or glucocorticoid-induced osteopenia or osteoporosis, osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, for the improvement of fracture healing after traumatic or atraumatic fracture, and for the maintenance or increase of energy level, for building up or strengthening muscle tissues and for weight gain, the method comprising administering to a subject in need thereof a) a strontium-containing compound and b) one or more further active substances capable of reducing the incidence of bone fracture and / or increasing bone density and / or improving healing of fractured bone.

[0008] In one embodiment of the method, the strontium-containing compound and one or more further active substances capable of reducing the incidence of bone fracture and / or increasing bone density and / or improving healing of fractured bone are administered in amounts that render the combination of the two effective in treating a cartilage and / or bone disease.

Problems solved by technology

The mechanism of bone loss in osteoporosis is believed to involve an imbalance in the process of bone remodeling.

However, in people with osteoporosis an imbalance in this remodeling process develops, resulting in loss of bone at a rate faster than the accretion of bone.

The decline in endogenous oestrogen production leads to an elevated metabolic activity in the bone tissue where the increase in osteoclast mediated bone resorption surpasses the more modest increase in bone formation, resulting in a net loss of bone.

SERM's and especially HRT is associated with significant side effects, such as increased risk of cancer and cardiovascular disease, whereas bisphosphonates in addition to a potent antiresorptive effect also decreases bone formation to a similar extent, implying that they loose their therapeutic effect after few years of treatment.

Images